Cowen Inc’s Alexion Pharmaceuticals ALXN Stock Holding History

Cowen Inc’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-107,200	Closed	-$19.4M	–	466
2015 Q2	$19.4M	Buy	+107,200	New	+$18.5M	1.17%	13

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Cowen Inc's ALXN Position: Q4 2016 in Review

Cowen Inc sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 6,000 shares — an estimated $735K sold.

Cowen Inc first reported a position in ALXN in Q1 2015 and held it in 7 quarters. The position peaked at $823K in Q2 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Cowen Inc reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Cowen Inc sold 6,000 Alexion Pharmaceuticals shares in Q4 2016, an estimated $735K.
Cowen Inc first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Cowen Inc's Alexion Pharmaceuticals position peaked at $823K in Q2 2015.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Cowen Inc's 13F filing for Q4 2016, filed 13 Feb 2017.